Marksans Pharma Limited, engaged in research, manufacturing & marketing of generic pharmaceutical formulation in the global markets, Q4 FY21 profit stood at Rs. 79.5 crore, a growth of 86% YoY. 

The company's operating revenue for Q4 FY21 was Rs. 330.2 crore as compared to Rs. 335.3 crore in Q4 FY20 due to deferment of certain sales in lockdown to next quarter. 

Operating revenue for FY 21 increased by 21.3% to Rs. 1,376.2 crore due to greater market depth in existing products coupled with new launches. PAT stood at Rs. 238.5 crore, Y-o-Y growth of 97.5%. Generated Cash from Operations and Free Cash Flow of Rs. 178.7 crore and Rs. 132.3 crore respectively. 

Marksans plans to incur capex of Rs. 200 crore over 2 years for both formulations and APIs. Currently the company is undergoing capacity expansion for softgel capsules in Goa. 

Working capital cycle increases on account of additional inventory to avoid any non-fulfilment of sales in the lockdown and also new product launches. 

Mark Saldanha, Managing Director & CEO, Marksans Pharma Limited said, "I am pleased to share that our all-round growth of 21.3% in FY21 was on the back of increasing wallet share with existing customers, addition of new logos and new product launches. Our investments in the US business is bearing fruit with EBITDA margin expansion to 24.7% brought about by operating leverage as well as an optimised product mix. We will continue to invest in our businesses to make ourselves future ready while remaining cautiously optimistic of continuing the growth traction in coming quarters.” 

Marksans Pharma Limited robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies.